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Mitochondrial DNA (mtDNA) diseases are inherited 
maternally by both male and female offspring, 
since all mitochondria are derived from the oocyte 
cytoplasm.[1] Most symptoms result in severe disability 
as the muscles, heart and other vital organs, which require high cellular 
energy production, are heavily affected. Currently, treatments for such 
syndromes are limited and supportive, aiming to hinder progression of 
the disease, rather than restorative.[2] The most severely affected patients 
die very young having lived a very poor quality of life.[3,4] Alternative 
therapies are needed, including those which are preventative. However, 
with developments in mitochondrial transfer techniques many ethical 
issues have been raised in the health and public sectors regarding these 
novel treatment options.
Many papers have provided insight into possible cures for human 
mtDNA disorders via transfer of nuclear material into donated oocytes 
with healthy mitochondria, or the introduction of healthy donor 
mitochondria into the affected oocytes, using assisted reproductive 
technology (ART) techniques involving micromanipulation. These 
treatments could potentially prevent transmission of mitochondrial 
disease from an affected or carrier mother to her offspring. Spindle[5] 
and ooplasmic transfer[6,7] pre-fertilisation, and pronuclear[8] and 
blastomere nucleus transfer[9] post-fertilisation, have been explored 
to achieve this. Data from primate and human oocytes have shown 
spindle (Fig. 1a) and pronuclear transfer (Fig. 1b) to be the most viable 
thus far.[5,8,10-12] We address the ethical concerns that surround these 
concepts, discuss the legal positions in the UK, USA and South Africa, 
and propose the future clinical management of these techniques. 
Alteration of germ line genetics
Mitochondrial transfer has been closely associated with reproductive 
cloning because these technologies involve alteration of germ line 
genetics. Unlike gene therapy, in which only the DNA of the individual 
subjected to the treatment will undergo changes, these novel 
techniques involve the introduction of foreign mtDNA (from the 
donor oocyte) into the germ line, which will be inherited by offspring 
in later generations. A valid argument countering this concern is the 
fact that ooplasmic transfer has been applied clinically and given rise 
to the birth of several children.[6,7,13] Consequently, offspring of these 
female children can have completely different mtDNA make-up, 
especially if the bottleneck effect results in donor mtDNA comprising 
the higher proportion of total mtDNA in their oocytes. This means 
that there will be mostly donor mtDNA expansion in the embryo, and 
therefore subsequent generations. Surprisingly, to date, no long-term 
follow-up studies have been conducted on these children.[14]
Regarding cloning concerns, which are often associated 
with mitochondrial transfer, reproductive adult cloning must be 
distinguished from reproductive embryo cloning. Adult cloning 
involves the transfer of adult (diploid) nuclear material into an 
enucleated oocyte. In contrast, the cell to be transferred in embryo 
cloning originates from an embryo.[15] The latter implies that the 
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resulting child will be the first of its kind and 
not a clone of an already existing human. 
However, many from the professional health 
and public sectors reject this technology. 
Internationally, there are differing bioethical 
and legal regulations concerning human 
cloning (for reproductive, therapeutic and 
research purposes). A report in 2006[16] 
summarised these regulatory approaches 
from 16 countries. Cloning concerns are 
especially applicable to the blastomere 
nuclear transfer technique, where a 
blastomere is derived from an embryo that 
consists of several cells, not just a single cell as 
found during transfer of spindles or pronuclei 
(Fig. 1). Potentially, several blastomeres could 
be transferred to several enucleated oocytes 
and give rise to genetically identical offspring. 
The blastomeres of a single embryo could 
be used on different occasions resulting in 
‘delayed’ twins.[17] This could be avoided by 
using one embryo per recipient oocyte, or 
one embryo per cycle. Alternatively, a multiple 
embryo transfer can be performed if multiple 
blastomeres of a single embryo are used 
for multiple recipient oocytes. Additionally, 
a completely new cycle could be initiated for 
each potential pregnancy.[17] The approach 
would be unique to each patient, depending 
on how many embryos are available and 
how many resultant embryos survive and 
implant. 
Is ‘three-parent IVF’ a 
sensationalised term?
The second ethical issue is the dilemma 
of children inheriting DNA material from 
three instead of two parents. The prevention 
of mtDNA disease transmission has been 
dubbed ‘three-parent IVF’. The general public 
have been led to believe that this will cause 
psychosocial problems for children born from 
these techniques, as they might experience 
an identity crisis. Three gametes are needed 
to produce a healthy embryo in this scenario. 
However, a crucial point is that the child will 
inherit all nuclear DNA from the intending 
parents, while only inheriting the mtDNA from 
the donor. Mitochondrial DNA possesses less 
than 30 genes, while nuclear DNA encodes 
approximately 25 000 genes. Furthermore, 
mtDNA is highly conserved among humans 
(Professor Douglas C. Wallace, University of 
Pennsylvania, personal communication), and 
to an extent across species, as mitochondrial 
energy production is a universal function 
required by all living organisms. By scale of 
quantity (number of genes) and quality (gene 
function), it is misleading for a resultant child 
to be led to believe that its physical attributes 
are derived from three, not two, sets of 
parental DNA.[18] 
On the other hand, it can be questioned 
whether some phenotypic characteristics 
are highly accounted for by the mtDNA – 
physical strength or sports ability, for 
instance. Unfortunately, such an argument 
is not applicable in a clinical setting where a 
couple is unable to have a healthy child that 
can live to adulthood. Their primary concern 
is not whether their child will inherit the best 
mitochondria possible to become an olympic 
athlete. Furthermore, it has not been proven 
whether physical strength can be attributed 
to specific variants of mtDNA genes, mtDNA 
mutations with an evolutionary advantage, or 
number of mtDNA copies. Perhaps, physical 
ability is only partially or completely unrelated 
to the sequence or natural reserve of mtDNA. 
Nuclear genes and physical practice could be 
more responsible for this phenotype.  
Other kinship forms that challenge the 
argument of loss of identity in children with 
‘three’ parents include adoption, surrogacy and 
use of donor gametes (sperm or oocytes alike) 
or gestational carriers. Such children could 
experience the same psychosocial issues.[18] 
While not possessing DNA from three parents, 
they have the potential to experience a crisis 
in terms of how they fit into their families, as in 
Fig. 1. Spindle(a) and pronuclear(b) transfer techniques. 
ICSI = intracytoplasmic sperm injection. mtDNA = mitochondrial DNA. nDNA = nuclear DNA. IVF =  in vitro fertilisation.
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theory they have more than two biological and social parents. Applying 
this sensationalism on a broader scale, would children born through 
embryo donation then have four parents? Nevertheless, researchers 
have suggested that if a paternal female relative is available and willing 
to donate oocytes for the mitochondrial transfer treatment, offspring will 
inherit paternal mtDNA and all nuclear DNA of the intending parents. 
Thereby the child will theoretically not possess any ‘foreign’ DNA from a 
third party.[9] Additionally, excluding adoption, all cases have a genetic 
aspect involved. Use of donor gametes and surrogate mothers, of 
course, result in a complete difference of genetic material between the 
child and one of the intending parents, causing them to be biologically 
unrelated. With regard to the use of surrogacy or a gestational carrier, 
the development of the fetus does not take place in the intending 
mother’s uterus. This alteration of the developmental environment causes 
epigenetic alterations in the fetal DNA. In this way, the woman that 
carries the child makes an indirect genetic contribution to the child since 
epigenetic DNA changes do modify the child’s phenotype and can even 
cause disease.[19]
On the grounds that adoption, fostering, step-parenting, surrogacy, 
and gamete donation are widely accepted in society today, the use of 
mitochondrial donors is only an extension of current forms of kinship. It 
seems unlikely that individuals born by these novel procedures would 
experience more or any psychosocial issues. Researchers conducting 
evaluations of donor conceived children consider that persons born 
through mitochondrial transfer techniques would better fit into the 
category of naturally conceived children, than donor conceived children, 
when it comes to their psychological wellbeing.[20] The mitochondrial 
donor should not necessarily be regarded as a second mother or parent 
to the resulting child, as this is refutable on both biological and legal 
principles (‘Mater semper certa est’). There is also evidence that individuals 
usually cope quite well with information regarding their origins (be 
they genetic, biological and/or social) provided that they are told at 
a relatively young age (during their pre- or primary school years) and 
in a controlled manner.[21] It is probably advisable for children born by 
preventative mtDNA disease techniques to be informed at an early age, 
and that this is reported to them with sufficient information about the 
procedures and relatively small genetic contribution from the donor. 
Future management  
The Nuffield Council on Bioethics of the United Kingdom (UK)[22] has 
reviewed the novel micromanipulation techniques, which can be 
utilised for the prevention of mtDNA disorders. The report concluded 
no overall ethical objection to the use of these technologies in humans 
for treatment of mtDNA disease, although further investigation is 
needed to confirm the safety of the techniques. They also recommend 
that patients are provided with appropriate information and support 
before and throughout the treatment. Suitably trained and updated 
individuals should deliver information to prospective patients. 
To broaden our knowledge and monitor the outcome of these 
therapies, the Nuffield Council also advises follow-up and assessment of 
the resulting children. In terms of regulation, other recommendations 
also stipulate that the status of mitochondrial donors should differ 
from oocyte or embryo donors and their identity need not necessarily 
be disclosed to the children once they reach adulthood.[22] This could 
potentially be a positive feature of this type of donation and result 
in more women being willing to donate their oocytes for these 
treatments, as the legalities of gamete donation can discourage some 
persons from donating. In 2014 the UK government proposed change 
in legislation to grant mitochondrial donors anonymity.[23] 
The Food and Drug Administration (FDA) of the USA, in February 
2014, discussed drafting guidelines for the design of clinical trials, 
but has not published the final document. It was acknowledged that 
clinical research would also be needed for validation of mitochondrial 
replacement to treat female infertility. The committee agreed on 
inclusion criteria for participants and the use of ‘historical controls’. 
Manufacturing controls and quality assessment of techniques, 
and how these factors could contribute to risk reduction for the 
participants and their future children, were also discussed. The FDA 
Cellular, Tissue and Gene Therapies Advisory Committee concluded 
that currently there is a lack of animal data to commence human 
clinical trials. Some members suggested additional research in 
alternative animal species concurrently as no single model emulates 
human physiology. Aspects to be considered in these studies to 
supplement current data include: 
• Sufficient subject numbers
• Evaluation from embryonic to postnatal stages
• Follow-up (including analysis of neurologic, cardiopulmonary and 
motor function)
• Assessment of the redox state
• Mitochondrial carryover
• Adverse nuclear-mitochondria interaction.
Other concerns raised included risks to the fetus and resulting 
children, many of which mirrored those in the UK report. Additionally, 
the committee reviewed the ethics of participation of these future 
children in clinical trials without informed consent. The FDA 
recommends setting up ‘centres of excellence’ in order to achieve 
standardisation of mitochondrial manipulation methods.[24] 
Undoubtedly, mitochondrial replacement therapy has a worthy 
place in assisted reproduction in the near future, as its benefit 
outweighs the associated ethical issues. Safety and efficacy must be 
optimised before human use but there is hope for families that want 
to prevent transmission of a mitochondrial disorder to their offspring. 
When developing a new medical therapy one needs to consider first 
and foremost alleviation of suffering to the patients and their families. 
Genetic manipulation in South Africa
The South African National Health Act 61 of 2003 (NHA), Chapter 
8: ‘Control of use of Blood, Blood Products, Tissue and Gametes in 
Humans’ [25] states:
‘A person may not – 
(a) manipulate any genetic material, including genetic material of 
human gametes, zygotes or embryo; or
(b) engage in any activity, including nuclear transfer or embryo splitting,
for the purpose of the reproductive cloning of a human being.’
The document further defines ‘reproductive cloning of a human 
being’ as: ‘the manipulation of genetic material in order to achieve the 
reproduction of a human being and includes nuclear transfer or embryo 
splitting for such purpose’. 
The NHA does not mention alteration of germ line genetics or 
reproductive embryo cloning. Transfer of mtDNA even in the form 
of blastomere nuclei (the technique which has been scrutinised the 
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most by ethicists) is not ‘reproductive cloning of a human being’. The 
document also does not specify that genetic material may not be 
manipulated for any other reasons. Does this mean that one could 
undertake mitochondrial transfer in the realms of the South African 
legal context? It is likely that ministerial authorisation will be required.
Concluding remarks and perspectives
Both the social and scientific aspects of a new healthcare technology 
must be considered. Regarding social and moral principles, many believe 
that some ART techniques go beyond the border of acceptable medical 
intervention. It is reasonable that these opinions should be considered, 
but who decides on what is globally acceptable and what is not? Diverse 
social, ethical, religious, cultural, political, scientific and clinical bodies 
will have differing attitudes. Public opinion can also make a difference 
today, more than it could in the past. However, is the public aware of 
techniques that have been in place for decades in assisted reproduction 
technology, without appropriate evidence-based data being gathered 
before implementation? The introduction of novel germ line therapies 
into humans has proved how important it is for the gap between 
scientific fact and public opinion to be overcome. The Nuffield Council on 
Bioethics has achieved this through a comprehensive review of the issues 
surrounding prevention of mtDNA disease by examining the techniques 
from many angles. The report also highlighted how some features of the 
therapies do not truly deviate from what is already considered socially 
acceptable.[22] However, once mitochondrial transfer becomes available 
to patients, long-term follow-up monitoring of the resultant children 
born by these techniques must be performed. 
The UK Department of Health has published draft regulations for new 
techniques to prevent the transmission of mitochondrial disease.[26] These 
regulations suggest creation of a national or worldwide database that 
can easily be accessed to encourage information sharing of patient data 
and improvement and optimisation of the techniques. The UK parliament 
has debated mitochondrial transfer since 2012[27,28] and in February 2015 
finally voted in favour of human mitochondrial replacement legalisation 
to allow the commencement of human clinical application. These Human 
Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 
will apply from 29 October 2015.[29] 
With regard to South African legislation,[25] alteration of germ line 
genetics and cloning other than reproducing human beings is not 
mentioned, and it is not clear whether the lack of information on 
these techniques implies that they are not prohibited. 
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